Adverse drug reactions

BMJ

Volumn 316, Issue 7140, 1998, Pages 1295-

  Pirmohamed, Munir ^a   Breckenridge, Alasdair M ^a   Kitteringham, Neil R ^a   Park, Kevin ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE DRUG REACTION; DOSE RESPONSE; DRUG SAFETY; HUMAN; IMMUNE SYSTEM; PRIORITY JOURNAL; SHORT SURVEY; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG SURVEILLANCE PROGRAM; IMMUNOLOGY; METABOLISM; REVIEW; RISK FACTOR;

DRUG;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG HYPERSENSITIVITY; HUMANS; IMMUNE SYSTEM; PHARMACEUTICAL PREPARATIONS; RISK FACTORS;

EID: 0032565185     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.316.7140.1295     Document Type: Article

References (39)

1. Asscher A.W. Parr G.D. Whitmarsh V.B. Towards the safer use of medicines. BMJ 1995;311:1003-1005.
2. Rawlins M.D. Pharmacovigilance: paradise lost, regained or postponed? J R Coll Physicians Lond 1995;29:41-49.
3. Einarson T.R. Drug-related hospital admissions. Ann Pharmacother 1993;27:832-840.
4. Bates D.W. Cullen D.J. Laird N. Petersen L.A. Small S.D. Servi D et al. Incidence of adverse drug events and potential adverse drug events—implications for prevention. JAMA 1995;274:29-34.
5. Bates D.W. Spell N. Cuilen D.J. Burdick E. Laird N. Petersen LA et al. The costs of adverse drug events in hospitalized patients. JAMA 1997;277:307-311.
6. Classen D.C. Pestotnik S.L. Evans R.S. Lloyd J.F. Burke J.P. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997;277:301-306.
7. Rawlins M.D. Thompson J.W. Mechanisms of adverse drug reactions. In: Ed. Davies DM ed. Textbook of adverse drug reactions. Oxford: Oxford University Press, 1991:18-19.
8. McKenzie R. Fried M.W. Sallie R. Conjeevaram H. Dibisceglie A.M. Park Y et al. Hepatic-failure and lactic-acidosis due to fialuridine (fiau), an investigational nucleoside analog for chronic hepatitis B. N Engl J Med 1995;333:1099-1105.
9. Lewis W. Levine E.S. Griniuviene B. Tankersley K.O. Colacino J.M. Sommadossi J-P et al. Fialuridine and its metabolites inhibit D.N. polymerase gamma at sites of multiple adjacent analog incoroporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci USA 1996;93:3592-3597.
10. Atkin P.A. Shenfield G.M. Medication-related adverse reactions and the elderly: a literature review. Adverse Drug Reactions Toxicol Rev 1995;14:175-191.
11. Harb G.E. Jacobson M.A. Human immunodeficiency virus infection: does it increase susceptibility to adverse drug reactions? Drug Safety 1993;9:1-8.
12. Park B.K. Pirmohamed M. Kitteringham N.R. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol 1992;34:377-395.
13. Pirmohamed M. Kitteringham N.R. Park B.K. The role of active metabolites in drug toxicity. Drug Safety 1994;11:114-144.
14. Williams R.T. The metabolism of foreign compounds and the detoxication mechanisms Detoxication mechanisms. New York: Wiley, 1959:717-718.
15. Shah R.R. Oates N.S. Idle J.R. Smith R.L. Lockhart JDF. Impaired oxidation of debrisoquine in patients with perhexilene neuropathy. BMJ 1982;284:295-298.
16. Pirmohamed M. Madden S. Park B.K. Idiosyncratic drug reactions: metabolic bioactivation as a pathogenic mechanism. Clin Pharmacokinet 1996;31:215-230.
17. Bray G.P. Liver failure induced by paracetamol. BMJ 1993;306:157-158.
18. Zimmerman H.J. Maddrey W.C. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995;22:767-773.
19. Nelson S.D. Molecular mechanisms of the hepatotoxicity caused by acetaminophen. Semin Liver Dis 1990;10:267-278.
20. Lauterburg B.H. Velez M.E. Glutathione deficiency in alcoholics: risk factor for paracetamol hepatotoxicity. Gut 1988;29:1153-1157.
21. Raucy J.L. Lasker J.M. Lieber C.S. Black M. Acetaminophen activation by human liver cytochromes P-45011E1 and P-4501A2. Arch Biochem Biophys 1989;271:270-283.
22. Lee S.S.T. Buters J.T.M. Pineau T. Fernandezsalguero P. Gonzalez F.J. Role of cyp2e1 in the hepatotoxicity of acetaminophen. J Biol Chem 1996;271:12063-12067.
23. Pohl L.R. Satoh H. Christ D.D. Kenna J.G. Immunologic and metabolic basis of drug hypersensitivities. Ann Rev Pharmacol 1988;28:367-387.
24. Park B.K. Coleman J.W. Kitteringham N.R. Drug disposition and drug hypersensitivity. Biochem Pharmacol 1987;36:581-590.
25. Weiss M.E. Adkinson M.F. Immediate hypersensitivity reactions to penicillin and related antibiotics. Clin Allergy 1988;18:515-540.
26. Park B.K. Pirmohamed M. Kitteringham N.R. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther 1995;68:385-424.
27. Pohl L.R. Drug-induced allergic hepatitis. Semin Liver Dis 1990;10:305-315.
28. Beaune P.H. Bourdi M. Autoantibodies against cytochrome P-450 in drug induced autoimmune hepatitis. Ann N Y Acad Sci 1993;685:641-645.
29. Friedmann P.S. Strickland I. Pirmohamed M. Park B.K. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 1994;130:598-604.
30. Koopmans P.P. van der Ven A.J.A.M. Vree T.B. van der Meer J.W.M. Pathogenesis of hypersensitivity reactions to drugs in patients with H.I. infection—allergic or toxic. AIDS 1995;9:217-222.
31. Van der Ven A.J. Koopmans P.P. Vree T.B. van der Meer J.W. Adverse reactions to co-trimoxazole in H.I. infection. Lancet 1991; 2: 431-432.
32. Roederer M. Staal F.J.T. Osada H. Herzenberg L.A. Herzenberg L.A. CD4 and C.D. T cells with high intracellular glutathione levels are selectively lost as the H.I. infection progresses. Int Immunol 1991;3:933-937.
33. Buhl R. Holroyd K.J. Mastrangeli A. Cantin A.M. Jaffe H.A. Wells FB et al. Systemic glutathione deficiency in symptom-free HlV-seropositive individuals. Lancet 1989; 2: 1294-1298.
34. Aukrust P. Svardal A.M. Muller F. Lunden B. Berge R.K. Ueland PM et al. Increased levels of oxidized glutathione in CD4+ lymphocytes associated with disturbed intracellular redox balance in human immunodeficiency virus type 1 infection. Blood 1995;86:258-267.
35. Pirmohamed M. Williams D. Tingle M.D. Barry M. Khoo S.H. O'Mahony C et al. Intracellular glutathione in the peripheral blood cells of HlV-infected patients: failure to show a deficiency. AIDS 1996;10:501-507.
36. Stricker BHC. Drug-induced hepatic injury., 2nd ed., Vol 5 Amsterdam: Elsevier Science, 1992.
37. Belton K.J. Lewis S.C. Payne S. Rawlins M.D. Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol 1995;39:223-226.
38. Smith C.C. Bennett P.M. Pearce H.M. Harrison P.I. Reynolds D.J.M. Aronson J.K. et al. Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol 1996;42:423-429.
39. Kessler D.A. Introducing MEDWatch: a new approach to reporting medication and device adverse effects and product problems. JAMA 1993;269:2765-2768.